AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05142449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive 8 capsules placebo perioperatively and for the next 3 days 6 capsules per day
Study NCT00856830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Drug Combination
Description: This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.~* All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.~* At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks.
Study NCT01031953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant dimeglumine
Description: A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.
Study NCT01031953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic chemotherapy
Description: Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated
Study NCT01031953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary
Study NCT01031953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
Study NCT00442923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coreg
Study NCT02213367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastin
Description: 80mg
Study NCT01483053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agomelatine
Description: Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
Study NCT01483053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
Study NCT03961048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally
Description: Variable initial post-operative dose of 10cc to 40cc bilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours bilaterally.
Study NCT03961048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally
Description: Variable initial post-operative dose of 10cc to 40cc unilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours unilaterally.
Study NCT04047524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Monitoring using a FitBit
Description: Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.
Study NCT04769687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotic Vivomixx®
Description: Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days). For the study, the symbiotics will be packaged in the same sachet at the same doses as mentioned above.
Study NCT00826943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: Cetirizine 10 mg tab daily x 7 days
Study NCT00826943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: 5 mg tab daily x 7 days
Study NCT00826943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily x 7 days
Study NCT04191031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ioveraº
Description: Cryoneurolysis
Study NCT04191031 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ioveraº sham
Description: ioveraº sham
Study NCT00260481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prometa
Description: Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
Study NCT00260481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
Study NCT01696825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam tablet, 5 mg, vaginal
Description: Diazepam tablet, 5 mg, moistened and inserted vaginally
Study NCT01696825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam tablet, 5 mg, vaginal
Description: Diazepam tablet, 5 mg, moistened and inserted vaginally
Study NCT01696825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Suppository, 5 mg, vaginal
Description: Compounded diazepam 5 mg suppository administered vaginally
Study NCT01696825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam Suppository, 5 mg, vaginal
Description: Compounded diazepam 5 mg suppository administered vaginally
Study NCT01696825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Cream, 5 mg, Vaginal
Description: Compounded diazepam cream, 5 mg, inserted vaginally
Study NCT01696825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam Cream, 5 mg, Vaginal
Description: Compounded diazepam cream, 5 mg, inserted vaginally
Study NCT02236975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA Supreme Biodegradable drug coating coronary stent system
Study NCT02236975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity durable polymer stent system
Study NCT00133497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF-59
Description: Microfluoridized adjuvant 59 (MF59).
Study NCT00133497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL of saline placebo.
Study NCT00133497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV gB vaccine
Description: CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
Study NCT02077920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~* Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~* Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving
Study NCT00585637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Taken orally every day for three months
Study NCT00585637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pill taken once daily for 3 month
Study NCT01595529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.
Study NCT01595529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Cephalexin 50mg/kg/day in 3 divided doses
Study NCT01595529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match the other four active treatments
Study NCT04769687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prebiotic Orafti®Synergy1
Description: Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
Study NCT04769687 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01595529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole
Description: 8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.
Study NCT01862406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Label
Description: Participants were presented with either a generic label or a brand-name label
Study NCT01862406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label
Description: Participants were presented with either a generic label or a brand-name label
Study NCT02484443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV
Study NCT02484443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02484443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02484443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT02840305 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of visual function
Study NCT02840305 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Study NCT01668940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lillipop Iced Soothies (Ginger flavour)
Description: Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
Study NCT02906930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once daily.
Study NCT03973112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10 3mg/kg
Description: anti-PD-1
Study NCT02906930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration once daily.
Study NCT01521182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-Fermented Dairy Product (test)
Description: 1 = Intervention 1 (test product)
Study NCT01521182 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2-Milk-based non-fermented dairy product (control)
Description: 2 = Intervention 2 (control product)
Study NCT03750435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation or left-sided AT ablation
Description: According to the type of AF/AT, single or double transseptal and subsequent catheter ablation in the left atrium using radiofrequency will be performed.
Study NCT00030992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-247550
Description: One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m\^2/day for a total per cycle dose of 30 mg/m\^2
Study NCT03086863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
Study NCT00030992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: 50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)
Study NCT00030992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
Study NCT02584400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection with the hypoxia tracer [18F]HX4,
Description: The \[18F\]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) \[18F\]HX4 via a bolus IV injection.
Study NCT00505089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Study NCT01104792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules.
Study NCT00686530 — intervention group
Intervention type: PROCEDURE
Intervention: MR Imaging
Description: Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.
Study NCT00686530 — intervention group
Intervention type: PROCEDURE
Intervention: Autopsy
Description: Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
Study NCT04112173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perturbation-based fall-recovery training
Description: Participants will attempt to recover from treadmill-induced balance perturbations as they walk or stand. The size of the perturbations is progressively challenging and dependent upon participant performance.
Study NCT03709823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: film coated tablet containing 1.5 mg cytisine in a single tablet
Study NCT03709823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 1.5 mg cellulose powder to match final weight of the cytisine tablet
Study NCT03709823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: 12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
Study NCT03709823 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral support
Description: 12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
Study NCT00948727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dose adaptation according to CN activity monitoring
Description: The protocol of the CALCICLO trial consisted in a CsA dose adaptation during the first 100 days following transplantation. This dose adaptation was performed according to both residual CsA blood and CN activity levels only if the safety of vital functions - especially renal, liver, and neurological - was preserved as assessed by clinical evaluations and laboratory analyses such as creatinine clearance higher than 40 ml/min, serum bilirubin lower than 40 µM and absence of neurological signs. According to the protocol, CsA blood levels and CN activity were measured concomitantly at least once a week from day 0 to day 15, twice a week from day 16 to day 35 and then once a week until day 100.
Study NCT00948727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Description: Cyclosporine (CsA)
Study NCT01516307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-822/OPT-821(30 μg/100 μg)
Description: Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.
Study NCT01516307 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Saline (PBS)
Description: Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
Study NCT01516307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
Study NCT01516307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
Study NCT04539886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellFX System
Description: CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)
Study NCT04539886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Electrodesiccation
Description: Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode
Study NCT02398773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT02398773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 16 Alpha-Fluoroestradiol
Description: Given IV
Study NCT03973112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04 5mg/kg
Description: anti-VEGF, a biosimilar to Avastin
Study NCT03086863 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
Study NCT03973112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04 10mg/kg
Description: anti-VEGF, a biosimilar to Avastin
Study NCT00910494 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Radiosurgery System IORT
Study NCT03322982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Description: less than 20% calories from fat daily
Study NCT03448016 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]
Description: Radiolabel
Study NCT03448016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOP-1A
Description: Tracer
Study NCT03816722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo2
Description: Treatment with HighFlow through the Airvo2 device, 8 hours per day
Study NCT03816722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: High flow treatment is investigated as an add on treatment to the personalized care already prescribed to the patients. As patients with interstitial lung disease very often demand very different treatment set ups treatment will vary in the individual patients. All will, however, be treated with ambulatory oxygen. Usual care will be unaltered a month before inclusion in the study in each of the individual patients
Study NCT00049257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Administered Day 1 of each cycle. AUC=6.
Study NCT00049257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: administered Days 1, 8, and 15 of each cycle. 100mg/m2
Study NCT05271747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AB-Kolicare
Description: Probiotic multi-strain formulation containing Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 for 21 days, 5 drops/day preferably during the first intake of milk